Where the health-insured are (and aren’t)

Massachusetts has the lowest percentage of residents lacking health insurance in the country. Texas has the highest.

WalletHub dug out the numbers and has posted its findings online. Here’s a snapshot of the states standing at the top and those that have no place to go but up:

States with lowest uninsured rates

1. Massachusetts (2.99%)

2. Rhode Island (4.09%)

3. Hawaii (4.16%)

4. Vermont (4.49%)

5. Minnesota (4.88%)

6. Iowa (5.01%)

7. New York (5.24%)

8. Wisconsin (5.71%)

9. Pennsylvania (5.77%)

10. Michigan (5.78%)

States with highest uninsured rates

41. North Carolina (11.26%)

42. Arizona (11.28%)

43. Nevada (11.42%)

44. Alaska (12.21%)

45. Wyoming (12.31%)

46. Mississippi (12.97%)

47. Florida (13.16%)

48. Georgia (13.41%)

49. Oklahoma (14.28%)

50. Texas (18.36%)

The credit and finance company also sliced and diced its findings city by city. Nine of the 10 least-insured cities (out of 548 included in the analysis) are in Texas, while seven of the 10 most-insured are in either Massachusetts or California.

To see WalletHub’s full coverage of this latest in its long-running series of national rankings surveys, click here.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.